前沿生物跌1.97% A股募20亿瑞银证券保荐上市

Group 1 - The core viewpoint of the news is that 前沿生物 (Frontier Biotech) is currently facing a decline in stock price, with its shares trading at 14.90 yuan, down 1.97%, and the company is in a state of stock price drop since its IPO [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an initial offering price of 20.50 yuan per share and a total issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance [1] - The highest stock price recorded on the listing day was 35.53 yuan, marking the peak since its IPO [1] Group 2 - The total amount raised from the initial public offering (IPO) was 184.418 million yuan, with a net amount of 171.729 million yuan after deducting issuance costs [1] - The company planned to use the raised funds for various projects, including the clinical development of an HIV fusion inhibitor, a combined therapy, a new transdermal analgesic patch, marketing network construction, and to supplement working capital [1] - The total issuance costs for the IPO (excluding VAT) amounted to 12.689 million yuan, with underwriting and sponsorship fees being 11.613 million yuan [1] Group 3 - The actual controller of the company is DONGXIE (谢东), who holds American nationality and has permanent residency in China [3] - In a subsequent issuance on September 22, 2022, the company issued 14.819 million shares at a price of 13.51 yuan per share, raising a total of 200.200 million yuan, with a net amount of 195.667 million yuan after deducting issuance costs [3] - The total fundraising from both issuances amounts to 2.044 billion yuan [4]